This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Immunomedics' Shares Surge YTD on Cancer Drug Approval
by Zacks Equity Research
Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.
Johnson & Johnson Gets European Approval for Ebola Vaccine
by Zacks Equity Research
J&J (JNJ) gets approval from the European Commission for Ebola vaccine.
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
by Kinjel Shah
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Why the Earnings Surprise Streak Could Continue for Merck (MRK)
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety
by Benjamin Rains
All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
by Zacks Equity Research
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
Pfizer's sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU Nod
by Zacks Equity Research
The FDA approves Pfizer (PFE) and Merck KGaA's sBLA for Bavencio as a first-line maintenance therapy for metastatic urothelial carcinoma. Daurismo gets the EU nod for acute myeloid leukemia.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - July 01, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
FDA Issues Guidance for Coronavirus Vaccine Developers
by Kinjel Shah
Around a dozen companies are developing a vaccine for the deadly coronavirus disease.
3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety
by Benjamin Rains
Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $76.12, marking a +1.24% move from the previous day.
Merck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda for recurrent or metastatic cutaneous squamous cell carcinoma, a form of skin cancer, gets approval from the FDA.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $77.12, moving +0.48% from the previous trading session.
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
by Zacks Equity Research
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
Pfizer Begins Four Phase III Studies on Vaccine Candidates
by Zacks Equity Research
Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.
Agenus Stock Up on Licensing Deal With China-Based Firm
by Zacks Equity Research
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
Novo Nordisk Completes Two Studies on Obesity Candidate
by Zacks Equity Research
Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
by Kinjel Shah
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
Merck's Keytruda Gets Accelerated Approval for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's accelerated approval.
Roche's Tecentriq With Chemotherapy Meets Goal for TNBC
by Zacks Equity Research
Roche's (RHHBY) phase III study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy meets goal in early TNBC patients.
The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $76.29 in the latest trading session, marking a -0.88% move from the prior day.